CCDC115

Across TCGA pan-cancer cohorts, CCDC115 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCDC115 data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCDC115 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CCDC115 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where CCDC115 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.864	0.967	<.001	32	view →
CCRCC	OS	Median	All	0.900	1.000	.010	13	view →
PDAC	OS	Tertile	III,IV	0.769	0.331	.016	12	view →
GBM	OS	Tertile	All	0.615	0.371	.001	12	view →
LSCC	DFS	Median	III,IV	0.584	0.938	.013	10	view →
HNSC	DFS	Quartile	II,III,IV	0.852	0.650	.036	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCDC115–LUAD (DFS)

Open the LUAD breakdown →